REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Rhea-AI Summary

REGENXBIO (Nasdaq: RGNX) announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference, scheduled for June 12, 2024, at 8:00 a.m. EDT in Miami, FL. The event will feature a fireside chat, accessible via live webcast on REGENXBIO's website, with an archived replay available for 30 days post-event.

Positive

• Participation in a high-profile event like the Goldman Sachs Annual Global Healthcare Conference increases visibility.
• Opportunity for direct engagement with investors and stakeholders.
• Webcast accessibility allows for broader reach and engagement.

Negative

• No immediate financial or clinical data disclosed in the press release.
• The impact on stock performance remains speculative without concrete outcomes from the event.

ROCKVILLE, Md., June 5, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024.

Goldman Sachs 45th Annual Global Healthcare Conference
Fireside Chat: Wednesday, June 12, 2024 at 8:00 a.m. EDT
Location: Miami, FL

A live webcast of the fireside chat can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.

Contacts:

Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-participate-in-the-goldman-sachs-45th-annual-global-healthcare-conference-302164157.html

SOURCE REGENXBIO Inc.

FAQ

When is REGENXBIO participating in the Goldman Sachs 45th Annual Global Healthcare Conference?

REGENXBIO is participating on June 12, 2024.

What time is the REGENXBIO fireside chat at the Goldman Sachs Conference?

The fireside chat is scheduled for 8:00 a.m. EDT on June 12, 2024.

Where can I access the REGENXBIO fireside chat webcast?

The live webcast can be accessed on the Investors section of REGENXBIO's website.

How long will the REGENXBIO webcast replay be available?

The replay will be available for approximately 30 days following the presentation.

Where is the Goldman Sachs 45th Annual Global Healthcare Conference taking place?

The conference is being held in Miami, FL.